These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28847163)

  • 1. Relamorelin for the treatment of gastrointestinal motility disorders.
    Chedid V; Camilleri M
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1189-1197. PubMed ID: 28847163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
    Camilleri M; McCallum RW; Tack J; Spence SC; Gottesdiener K; Fiedorek FT
    Gastroenterology; 2017 Nov; 153(5):1240-1250.e2. PubMed ID: 28760384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist.
    Camilleri M; Acosta A
    Neurogastroenterol Motil; 2015 Mar; 27(3):324-32. PubMed ID: 25545036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
    Lembo A; Camilleri M; McCallum R; Sastre R; Breton C; Spence S; White J; Currie M; Gottesdiener K; Stoner E;
    Gastroenterology; 2016 Jul; 151(1):87-96.e6. PubMed ID: 27055601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease.
    Zatorski H; Mosinska P; Storr M; Fichna J
    J Physiol Pharmacol; 2017 Dec; 68(6):797-805. PubMed ID: 29550791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
    Acosta A; Camilleri M; Kolar G; Iturrino J; Szarka LA; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR; Spence SC; Gottesdiener K; Bouras EP; Vazquez-Roque MI
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2312-9.e1. PubMed ID: 26001337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.
    Acosta A; Camilleri M; Busciglio I; Boldingh A; Nelson AD; Burton D
    Dig Dis Sci; 2016 Mar; 61(3):852-60. PubMed ID: 26467700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.
    Nelson AD; Camilleri M; Acosta A; Busciglio I; Linker Nord S; Boldingh A; Rhoten D; Ryks M; Burton D
    Neurogastroenterol Motil; 2016 Nov; 28(11):1705-1713. PubMed ID: 27283792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.
    Camilleri M; Lembo A; McCallum R; Tourkodimitris S; Kemps L; Miller MB; Bertelsen K; Iacob A
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1139-1148. PubMed ID: 32301137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drug therapies for the treatment of gastroparesis.
    Sanger GJ; Pasricha PJ
    Expert Opin Investig Drugs; 2017 Mar; 26(3):331-342. PubMed ID: 28127997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives.
    Stevens JE; Jones KL; Rayner CK; Horowitz M
    Expert Opin Pharmacother; 2013 Jun; 14(9):1171-86. PubMed ID: 23663133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety.
    Patel A; Arora GS; Roknsharifi M; Javed H; Kaur P
    Cureus; 2023 Nov; 15(11):e48303. PubMed ID: 38058346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic applications of ghrelin agonists in the treatment of gastroparesis.
    Shin A; Wo JM
    Curr Gastroenterol Rep; 2015 Feb; 17(2):430. PubMed ID: 25702264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ghrelin as a target for gastrointestinal motility disorders.
    Greenwood-Van Meerveld B; Kriegsman M; Nelson R
    Peptides; 2011 Nov; 32(11):2352-6. PubMed ID: 21453735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of treatment for gastroparesis.
    Sarosiek I; Bashashati M; McCallum RW
    Expert Opin Drug Saf; 2016 Jul; 15(7):937-45. PubMed ID: 27031006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials.
    Asha MZ; Khalil SFH
    Sultan Qaboos Univ Med J; 2019 Nov; 19(4):e291-e304. PubMed ID: 31897312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.
    Sanger GJ; Furness JB
    Nat Rev Gastroenterol Hepatol; 2016 Jan; 13(1):38-48. PubMed ID: 26392067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroduodenal motility disorders.
    Tack J; Van den Houte K; Carbone F
    Curr Opin Gastroenterol; 2018 Nov; 34(6):428-435. PubMed ID: 30199408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of ghrelin and growth hormone releasing peptide 6 on gastroparesis in streptozotocin-induced diabetic guinea pigs in vivo and in vitro.
    Qiu WC; Wang ZG; Wang WG; Yan J; Zheng Q
    Chin Med J (Engl); 2008 Jul; 121(13):1183-8. PubMed ID: 18710636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nausea and vomiting in diabetic and idiopathic gastroparesis.
    Cherian D; Parkman HP
    Neurogastroenterol Motil; 2012 Mar; 24(3):217-22, e103. PubMed ID: 22118574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.